Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    88,457.16
    +1,186.34 (+1.36%)
     

  • CMC Crypto 200

    1,387.94
    +75.32 (+5.74%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

HTG Molecular Diagnostics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 13

GlobeNewswire

TUCSON, Ariz., May 11, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the first quarter ended March 31, 2020 after the market close on Wednesday, May 13, 2020. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

Conference Call & Webcast Details

Date:

Wednesday, May 13

Time:

4:30 pm Eastern Time

Toll Free:

877-407-0789

International:

201-689-8562

Conference ID:

13703169

Webcast:

http://public.viavid.com/index.php?id=139651

About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.

Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com